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Introduction
Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive and lethal cancer in humans. Annually, approximately 43,000 people are diagnosed (incidence 10-12:100,000) with PDAC in the Unites States and the mortality rate of 36,800, almost equals this number [1] . The patients with potentially resectable disease are a minority (10%-15%) [2] . The median overall survival is less than 6 months and, despite surgery, the 5-year survival rate is a dismal 3 to 5%, with chemotherapeutic options having only a limited impact. Cancer is a complex disease involving numerous genetic and epigenetic changes, thus as a better understanding of the molecular mechanism of PDAC is urgently needed to develop an effective diagnosis and treatment [3] , these cancer related changes need to be investigated.
MicroRNAs (miRNAs) are a class of endogenous non-coding, single-stranded small regulatory RNA molecules, which are approximately 22 nucleotides in length [4] . MiRNAs inhibit translation via silencing mRNA molecules by cleaving mRNA after base-pairing to the 3' untranslated region of the target genes [5] [6] [7] . Previous studies indicated that miRNAs are not only involved in the pathogenesis of PDAC but also in the regulation of the response [8] ; additionally the miR-200 family has been shown to regulate epithelial to mesenchymal transition by targeting Zinc Finger E-box-binding 1 (ZEB1) and Zinc Finger E-box-binding 2 (ZEB2) and thus appears to have an important role in PDAC [9, 10] . In addition, receptorinteracting protein 1 (RIP1), a mediator in cell survival and death signaling, which participates in the cancer's response to chemotherapy, has been found to be regulated by miRNAs. In lung cancer knockdown of RIP1 was associated with robust JNK activation [11, 12] . Another study showed that the expression of miR-940 was substantially increased in RIP1 knockdown cells and that the knockdown of miR-940 restored MKP1 expression and attenuated cisplatininduced JNK activation and cytotoxicity [13] .
Here we focused on the role of miR-940 in PDAC. We found that low miR-940 level in PDAC tissues was correlated with low survival rate. We also investigated the effects of upand down-regulation of miR-940 in PDAC cell lines. Many of miR-940-targeted genes were predicted, including MyD88. MyD88 is a very key adaptor protein, which mediates numerous biologically important signal transduction pathways in innate immunity [14] [15] [16] [17] [18] . Thus the role of MyD88 in PDAC was also investigated.
In conclusion, our data showed that low level of miR-940 in PDAC promoted PDAC growth via MyD88. [21] .
Real time q-PCR
Real-time quantitative PCR analysis for miR-940 was performed by Shengong Company (Shanghai) using standard protocols on an Applied Biosystem's 7500 HT sequence Detection System. miR-940 expression was assessed using a mirVana TM qRT-PCR miRNA Detection Kit (Ambion, USA). The primers were designed and synthesized by Shengong Company (Shanghai). U6 as an internal control.
MTT assay
For MTT assay, 5×10 3 cells per well were seeded in triplicate in a 96-well plate with complete growth medium. Cells were counted over 5 days using the MTT assay (Promega, Fitchburg, WI, USA) as described WI, USA ).
Apoptosis assay
Cells from each group were harvested at 48 h post-transfection. Cells were resuspended at a density of 1×10 6 cells/mL in PBS. After double staining with FITC-Annexin V and propidium iodide (PI) using the cytometer (BD Biosciences) equipped with Cell Quest software (BD Biosciences). Annexin V + PI -cells were counted as apoptosis cells.
MicroRNAs targets prediction
TargetScanHuman (http://www.targetscan.org/vert_61/) [25] [26] [27] [28] was applied to identify the potential target of miR-940.
MiRNAs antisense, miRNAs mimics, oligonucleotides
MiRNA-940 function was explored by cell transfection experiment. MiR-940 mimics (Cat. no. MSY0004983), miR-940 ASO (Cat. no. MIN0004983) and negative control (Cat. no. MSY0002505) were purchased from Qiagen(Venlo, Limburg, the Netherlands). MiRNAs ASO, MiRNAs mimics, negative control (NC) were transfected into cells at a concentration of 50nM using Lipofectamine 2000 (Invitrogen, Canada) transfection reagent according to the manufacturer's instructions. 48h later cells were collected for further experiments.
MyD88 3'UTR reporter analysis
The MyD88 3'UTR reporter plasmid (pRL-MyD88) was constructed by Shengong Company (Shanghai, China). Mutation in the miR-940 seed regions of the MyD88 3'UTR was generated using QuikChang Multi site -directed mutagenesis kit (Promega, Fitchburg, WI, USA). RL reporter plasmids (3.6fmol) and pGL3-control (500ng for normalization) (Promega, Fitchburg, WI, USA) were transfected with Lipofectamine 2000 (Invitrogen, Canada) into HEK293 (6×10 4 cells per well). Cells were collected after 48h for assay using the Dual Luciferase reporter assay system (Promega, Fitchburg, WI, USA) [29] .
Western blot and antibodies
Tumor tissues were collected, lysed, and blotted as described previously [30] . Membranes were blocked with blocking solution (5% skim milk in TBST) and incubated with primary antibody, followed by the incubation with appropriate HRP-conjugated secondary antibody. The MyD88 antibody (anti-MyD88) was purchased from Santa Cruz Biotechnology, Inc. The densitometry of Western blot results was measured using ImageJ software.
Immunohistochemistry applied. Subsequent counterstaining was performed with hematoxylin. Immunostaining results for MyD88 were evaluated using a semi-quantitative scoring system as described previously [31] , which calculated the Alternatively, IHC score of MyD88 expression was (-~ +) and (++ ~ +++), which represented low and high expression, respectively.
MyD88 mRNA expression in PDAC analysis
The data of MyD88 mRNA in PDAC was queried from Gene Expression Omnibus (GSE15471).
Statistical Analysis
Data were presented as the mean ±s.d. from at least three independent experiments. The difference between groups were analyzed using two-tailed Student's t test when only two groups were compared. difference in the expression of miR-940 and MyD88 between matched pairs. The difference between groups were analyzed using ANOVA when three or more than three groups were compared. Correlation analysis Kaplan-Meier analysis. Statistical analyses were performed using SPSS software (version 17.0). P<0.05 was
Results

Low miR-940 level in PDAC tissues was correlated with low survival rate
MiR-940 level was assayed by qRT-PCR analysis in 78 pairs of PDAC tissues and the matched tumor-adjacent normal tissues. We found that 61 of the 78 tissues samples showed lower miR-940 level than in the matched tumor-adjacent normal tissues (Fig. 1A) . The mean level of miR-940 was lower in PDAC tissues than in matched tumor-adjacent normal tissues level of miR-940 was associated with overall survival in PDAC patients. To this end, the 78 PDAC patients, from whom the analyzed samples have been collected, were followed-up for 50 months. The median value of all 78 cases was chosen as the cutoff point for separating miR-940 high-expression cases from miR-940 low-expression cases. Survival curves showed than patients with low miR-940 levels (39 cases) (Fig. 1C) . We also assayed miR-940 level in PDAC cell lines and found that SW1990, and PANC1 cells expressed a lower level of miR-940 than pancreatic duct epithelial cell line, HPDE6 (Fig. 1D) .
Overexpression of miR-940 inhibited PDAC cell lines growth and induce cells apoptosis
We investigated the role of miR-940 in vitro, by overexpressing the level of miR-940 through transfection of miR-940 mimics in PANC1 and SW1990 cells. The effectiveness of assay 24 h post transfection, showed that the overexpression of miR-940 level inhibited the proliferation of the PANC1 and SW1990 cell lines. In addition, the evaluation of the effect of miR-940 on cell apoptosis in PANC1 and SW1990 cell by FACS revealed that overexpression of miR-940 led to increased cell apoptosis in both cell lines (Fig. 2C, D) .
Reduction of miR-940 promoted PDAC cell lines proliferation and inhibited cell apoptosis
We also investigated the effect of the inhibition of miR-940 by transfecting PANC1 and SW1990 cells with miR-940 ASO, expressing the miR-940 anti-sense oligonucleotide (ASO) to transiently suppress miR-940. We found that miR-940 ASO transfection suppressed the miR-940 level in the both cell lines (Fig. 3A) . Additionally, cells proliferation analysis by MTT assay after miR-940 ASO transfection revealed that the down-regulation of miR-940 mildly promoted cell proliferation in PANC1 and SW1990 cells (Fig. 3B) . Next cell apoptosis was assayed by FACS analysis, and found that suppression of miR-940 reduced cell apoptosis cells in PANC1 and SW1990 cells (Fig. 3C, D) . 
Cellular Physiology and Biochemistry
MyD88 was targeted by miR-940
We next explored the potential target genes of miR-940 by applying bioinformatics algorithm to predict miR-940-targeted genes. Many genes were predicted (data not shown), including the myeloid differentiation primary response gene (88) (MyD88). MyD88 is a key adaptor protein, which mediates numerous biologically important signal transduction pathway in innate immunity [14] [15] [16] [17] [18] . Because of its possible relevance to PDAC pathogenesis MyD88 was chosen for further investigation, and the binding site and mutated site in MyD88 were shown (Fig. 4A) . The intact 3'UTR of MyD88 and its mutated version were cloned into a luciferase reporter plasmids, which were used for co-transfection with miR-940 into HEK293 cells. We found that miR-940 reduced the luciferase activity of wild type 3' UTR and MyD88 at the protein level showed that MyD88 protein level was inhibited 48 h after miR-940 mimics transfection. Thus these data indicated that MyD88 was targeted by miR-940 (Fig. 4C) .
High MyD88 protein level in PDAC tissues was correlated with low survival rate
tissues specimens and the matched tumor-adjacent normal tissues specimens by immunohistochemistry (IHC). The MyD88 expression level was scored by comparison to the MyD88 level in normal tissues which was arbitrarily assigned a score of 1. Six representative cases were selected to illustrate the results. The scores of MyD88 level in the six cases were (Fig. 5B) . The evaluation of the mean expression level revealed that the mean MyD88 expression in 78 PDAC tissues was higher than that of the matched MyD88 over-expression in PDAC, by evaluating whether the levels of MyD88 expression were associated with overall survival in 78 PDAC patients who were followed up for 50 months. After measuring MyD88 expression, the median value of all 78 case was chosen as the cutoff point for separating MyD88 high expression cases from MyD88 low expression cases.
shorter overall survival (p=0.0026) than those with low MyD88 expression. The (Fig. 5D ). Next we explored Gene Expression Omnibus (GEO) for analysis of MyD88 mRNA expression in PDAC. And found that MyD88 expression in tumor tissues were higher than in adjacent normal tissue (p=3.14×10 -7 ) (Fig. 5E )
MyD88 over-expression partly reduced the inhibitory effect of miR-940
The correlation between miR-940 and MyD88 was analyzed by Pearson's correlation PDAC tissues (Fig. 6A) . Furthermore, proliferation analysis of cells over-expressing MyD88 after miR-940 mimics transfection, by MTT assay, revealed that MyD88 over-expression partly reduced the anti-proliferative effect of miR-940 on these cells (Fig. 6B ).
Discussion
In this study, we found that low level of miR-940 level and high level of MyD88 protein in PDAC tissues were both correlated with low survival rate in PDAC patients. We also found The role of miR-940 in prostate cancer was revealed by other study [32] . They found that miR-940 suppresses prostate cancer migration and invasion by regulating migration and invasion enhancer 1.
In our previous study, we found that miR-545 inhibited PDAC growth by targeting RIG-I [33] . It seemed that miR-940 exerted multifunction in different cancers, and the growth of PDAC was regulated by many miRNAs through different targeted genes response, and its mediated numerous biologically important signal transduction pathway in innate immunity [14] [15] [16] [17] [18] .
It is known that TLR signaling were involved in pancreatic cancer associated inhibition exerts protective effect. However, directly blocking MyD88 signaling results in paradoxically pro-tumorigenic outcomes [35, 36] . Because MyD88 inhibition in dendritic cells caused them to skew CD4 + T cells toward a T H regulate the expression of MyD88. Unlike direct MyD88 inhibition led catastrophic results, miR-940 could inhibit PDAC cells growth. Although our data came from in vitro experiment, we believed the role miR-940 in PDAC and in dendritic cells needed further investigation.
In conclusion, our study revealed the role of miR-940 in PDAC, and found low expression of miR-940 in PDAC cell lines promoted cell proliferate by MyD88. We hoped that our study may provide some hint for other PDAC research.
